Navigation Links
Successful Drug Re-Launch Hinges on Organizational Backing
Date:3/25/2008

CHAPEL HILL, N.C., March 25 /PRNewswire/ -- There is no guarantee that a re-launch will revitalize a drug that fizzled after its initial launch. A necessary first step for a successful re-launch is to win the organizational backing that ensures needed resources -- both financial and staffing -- will go into the effort, according to a study by benchmarking leader Best Practices, LLC.

The study, Product Relaunch Excellence: Transforming Lackluster Pharmaceutical Products into Market Success Stories, found that leading companies spend more than 100 percent of the initial launch investment to successfully establish a brand identity for the re-launched product. But that investment can pay off quickly: Leading pharmaceutical companies expect at least a 20 percent increase in annual sales with a re-launch, according to the study.

The report is available online with a complimentary excerpt at http://www3.best-in-class.com/rr919.htm .

The study gathers insights from 14 pharmaceutical and biotech companies, including Abbott Labs, AstraZeneca, GlaxoSmithKline, Merck, Novartis, Pfizer and Sanofi-Aventis. The study contains almost 500 metrics and 50 best practices that will help executives gain insights into re-launch strategy and practices.

Field research revealed that companies employ a systematic investment management process to build the business case for investing in a re-launch. The process can be summarized as a four-step cycle:

-- Rally for Resources - It is critical to gain organizational support and

buy-in to prevent the lack of resources from becoming a roadblock to

re-launching.

-- Determine the Level of Investment - Depending on the level of re-

positioning and re-vamping required, companies must determine the level

of investment needed.

-- Create the Investment Allocation - Companies essentially share the same

approach in that the majority of investment, almost two-thirds, is

shared by sales, various promotional channels, KOL and advocacy

initiatives.

-- Refine the Marketing Mix - After re-launch, monitor and adjust the

plan. During the two or three quarters it takes to access the

penetration success of key customer segments, brand teams carefully

observe the impact of marketing.

For a deeper exploration of the captured metrics and best practices in the study, visit http://www3.best-in-class.com/rr919.htm or for related research visit our Best Practices, LLC Web site at: http://www3.best-in-class.com/.

ABOUT BEST PRACTICES, LLC

Best Practices, LLC is a research and consulting firm that conducts work based on the principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Our clients include 43 of the 50 leading pharmaceutical companies. For more information, call (919) 403-0251 or visit http://www3.best-in-class.com/ .


'/>"/>
SOURCE Best Practices, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cancer treatments in phase 3 trials successful up to half of the time
2. Scientists successfully awaken sleeping stem cells
3. Unions Successful in Targeting Healthcare Industry
4. Researchers develop a method to select eggs with the best chance of leading to successful pregnancy
5. Milestone Scientific Announces Chicago Dental Societys 143rd Midwinter Meeting Proved Successful
6. Despite popularity, researcher finds not everyone can successfully learn through online courses
7. The Ensign Group Successfully Graduates Troubled Nursing Home from CMS Special Focus Facility Program
8. Successful Massachusetts Healthcare Reform Initiative Faces Rising Healthcare Costs in Year Two
9. Redefining a Products Identity Key to a Successful Re-Launch
10. Kiadis Pharma Announces Successful Completion of Rhitol(TM) Phase II Clinical Study
11. Lilly Caps Successful Year with Strong Fourth-Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... , ... Many families have long-term insurance that covers care for a family ... for care if the client has a cognitive impairment diagnosis. , “What this ... often waived, so the benefits from their insurance start immediately,” said Mechell Vieira, owner ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and ... explains one of the most popular and least understood books in the Holy Scriptures, ... puzzling descriptions that have baffled scholars for centuries. Many have tossed it off as ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... -- Cohen Veterans Bioscience and Early Signal Foundation announce ... home sensors for real-time monitoring of patients with trauma-related ... organization focused on disruptive health solutions for rare disorders ... to record and integrate behavioral, cognitive, physiological and contextual ... ...
(Date:9/27/2017)... Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a leading global digital ... its MyDario product is expected to appear on The Dr. Oz Show ... Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz Show kicked off ... The segment features ...
(Date:9/25/2017)... 2017  EpiVax, Inc., a leader in the ... today announced the launch of EpiVax Oncology Inc., ... therapeutic cancer vaccines. EpiVax has provided $500,000 in ... enabling technologies to the new precision immunotherapy venture. ... Oncology as Chief Executive Officer. Gad brings over ...
Breaking Medicine Technology: